Effects of apricitabine and other nucleoside reverse transcriptase inhibitors on replication of mitochondrial DNA in HepG2 cells

Antiviral Research

Volumn 76, Issue 1, 2007, Pages 68-74

  de Baar, Michel P ^a   de Rooij, Esther R ^a   Smolders, Karlijn G M ^a   van Schijndel, Harm B ^a   Timmermans, Eveline C ^a   Bethell, Richard ^b  

^a Primagen   (Netherlands)

^b Shire Canada   (Canada)

Author keywords

Apricitabine; Mitochondrial DNA; NRTI

Indexed keywords

3' FLUOROTHYMIDINE; ABACAVIR; APRICITABINE; AVX 754; CYTIDINE DERIVATIVE; DIDANOSINE; EMTRICITABINE; GENOMIC DNA; LAMIVUDINE; MITOCHONDRIAL DNA; RNA DIRECTED DNA POLYMERASE INHIBITOR; SPD 754; STAVUDINE; TENOFOVIR; UNCLASSIFIED DRUG; ZALCITABINE; ZIDOVUDINE;

ARTICLE; CELL CULTURE; CELL STRAIN HEPG2; CONTROLLED STUDY; DRUG EFFECT; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MITOCHONDRIAL DNA REPLICATION; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL;

ADENINE; DEOXYCYTIDINE; DNA REPLICATION; DNA, MITOCHONDRIAL; HEPATOCYTES; HUMANS; PHOSPHONIC ACIDS; REVERSE TRANSCRIPTASE INHIBITORS;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 34547421241     PISSN: 01663542     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.antiviral.2007.05.004     Document Type: Article

References (31)

1. Barile M., Valenti D., Quagliariello E., and Passarella S. Mitochondria as cell targets of AZT (zidovudine). Gen. Pharmacol. 31 (1998) 531-538
2. Benbrik E., Chariot P., Bonavaud S., Ammi-Said M., Frisdal E., Rey C., Gherardi R., and Barlovatz-Meimon G. Cellular and mitochondrial toxicity of zidovudine (AZT), didanosine (ddI) and zalcitabine (ddC) on cultured human muscle cells. J. Neurol. Sci. 149 (1997) 19-25
3. Bethell R.C., Parkin N., and Lie Y. Antiviral activity of SPD754 against clinical isolates of HIV-1 resistant to other nucleoside reverse transcriptase inhibitors. Antiviral Ther. 8 (2003) S6
4. Birkus G., Hitchcock M.J., and Cihlar T. Assessment of mitochondrial toxicity in human cells treated with tenofovir: comparison with other nucleoside reverse transcriptase inhibitors. Antimicrob. Agents Chemother. 46 (2002) 716-723
5. Brinkman K., and Kakuda T.N. Mitochondrial toxicity of nucleoside analogue reverse transcriptase inhibitors: a looming obstacle for long-term antiretroviral therapy?. Curr. Opin. Infect. Dis. 13 (2000) 5-11
6. Brinkman K., ter Hofstede H.J.M., Burger D.M., Smeitink J.A., and Koopmans P.P. Adverse effects of reverse transcriptase inhibitors: mitochondrial toxicity as common pathway. AIDS 12 (1998) 1735-1744
7. Brinkman K., Smeitink J.A., Romijn J.A., and Reiss P. Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy. Lancet 354 (1999) 1112-1115
8. Cahn P., Cassetti I., Wood R., Phanuphak P., Shiveley L., Bethell R.C., and Sawyer J. Efficacy and tolerability of 10-day monotherapy with apricitabine in antiretroviral-naïve, HIV-infected patients. AIDS 20 (2006) 1261-1268
9. Cazzalini O., Lazze M.C., Iamele L., Stivala L.A., Bianchi L., Vaghi P., Cornaglia A., Calligaro A., Curti D., Alessandrini A., Prosperi E., and Vannini V. Early effects of AZT on mitochondrial functions in the absence of mitochondrial DNA depletion in rat myotubes. Biochem. Pharmacol. 62 (2001) 893-902
10. Chen C.H., and Cheng Y.C. Delayed cytotoxicity and selective loss of mitochondrial DNA in cells treated with the anti-human immunodeficiency virus compound 2′, 3′-dideoxycytidine. J. Biol. Chem. 264 (1989) 11934-11937
11. Chen C.H., Vazquez-Padua M., and Cheng Y.C. Effect of anti-human immunodeficiency virus nucleoside analogs on mitochondrial DNA and its implication for delayed toxicity. Mol. Pharmacol. 39 (1991) 625-628
12. de la Asuncion J.G., del Olmo M.L., Sastre J., Millan A., Pellin A., Pallardo F.V., and Vina J. AZT treatment induces molecular and ultrastructural oxidative damage to muscle mitochondria. J. Clin. Invest. 102 (1998) 4-9
13. Dornsife R.E., and Averett D.R. In vitro potency of inhibition by antiviral drugs of hematopoietic progenitor colony formation correlates with exposure at hemotoxic levels in human immunodeficiency virus-positive humans. Antimicrob. Agents Chemother. 40 (1996) 514-519
14. Faraj A., Fowler D.A., Bridges E.G., and Sommadossi J.P. Effects of 2′, 3′-dideoxynucleosides on proliferation and differentiation of human pluripotent progenitors in liquid culture and their effects on mitochondrial DNA synthesis. Antimicrob. Agents Chemother. 38 (1994) 924-930
15. Flexner C., van der Horst C., Jacobson M.A., Powderly W., Duncanson F., Ganes D., Barditch-Crovo P.A., Petty B.G., Baron P.A., and Armstrong D. Relationship between plasma concentrations of 3′-deoxy-3′-fluorothymidine (alovudine) and antiretroviral activity in two concentration-controlled trials. J. Infect. Dis. 170 (1994) 1394-1403
16. Gu Z., Nguyen-Ba N., Ren C., et al. Novel cytidine analogue BCH-10618 is Active against different clades and types of drug resistant HIV-1. First International AIDS Society Conference on HIV Pathogenesis and Treatment. Buenos Aires, Argentina, July 8-11 (2001) Abstract 244
17. Johnson A.A., Ray A.S., Hanes J., Suo Z., Colacino J.M., Anderson K.S., and Johnson K.A. Toxicity of antiviral nucleoside analogs and the human mitochondrial DNA polymerase. J. Biol. Chem. 276 (2001) 40847-40857
18. Kakuda T.N. Pharmacology of nucleoside and nucleotide reverse transcriptase inhibitor-induced mitochondrial toxicity. Clin. Ther. 22 (2000) 685-708
19. Kievits T., van Gemen B., van Strijp D., Schukkink R., Dircks M., Adriaanse H., Malek L., Sooknanan R., and Lens P. NASBA isothermal enzymatic in vitro nucleic acid amplification optimized for the diagnosis of HIV-1 infection. J. Virol. Methods 35 (1991) 273-286
20. Lim S.E., and Copeland W.C. Differential incorporation and removal of antiviral deoxynucleotides by human DNA polymerase gamma. J. Biol. Chem. 276 (2001) 23616-23623
21. Nerurkar P.V., Pearson L., Frank J.E., Yanagihara R., and Nerurkar V.R. Highly active antiretroviral therapy (HAART)-associated lactic acidosis: in vitro effects of combination of nucleoside analogues and protease inhibitors on mitochondrial function and lactic acid production. Cell. Mol. Biol. (Noisy-le-Grand) 49 (2003) 1205-1211
22. Pan-Zhou X.R., Cui L., Zhou X.J., Sommadossi J.P., and Darley-Usmar V.M. Differential effects of antiretroviral nucleoside analogs on mitochondrial function in HepG2 cells. Antimicrob. Agents Chemother. 44 (2000) 496-503
23. Sundseth R., Joyner S.S., Moore J.T., Dornsife R.E., and Dev I.K. The anti-human immunodeficiency virus agent 3′-fluorothymidine induces DNA damage and apoptosis in human lymphoblastoid cells. Antimicrob. Agents Chemother. 40 (1996) 331-335
24. Timmermans E.C., Tebas P., Ruiter J.P.N., Wanders R.J.A., de Ronde A., and de Baar M.P. Real-time nucleic acid sequence-based amplification assay to quantify changes in mitochondrial DNA concentrations in cell cultures and blood cells from HIV-infected patients receiving antiviral therapy. Clin. Chem. 52 (2006) 979-987
25. Tyagi S., and Kramer F.R. Molecular beacons: probes that fluoresce upon hybridization. Nat. Biotechnol. 14 (1996) 303-308
26. Velsor L.W., Kovacevic M., Goldstein M., Leitner H.M., Lewis W., and Day B.J. Mitochondrial oxidative stress in human hepatoma cells exposed to stavudine. Toxicol. Appl. Pharmacol. 15 (2004) 10-19
27. Waclawik A.J., Vann J., Schmelz G., Szurek P., Lewandoski P., and Brooks B.R. Zidovudine (AZT) myotoxicity: quantitative separation of AZT effects on proliferation and differentiation of muscle cells in vitro. Lack of myotoxicity potentiation by retrovirus. Neurotoxicology 20 (1999) 49-56
28. Walker U.A. Clinical manifestations of mitochondrial toxicity. J. HIV Ther. 6 (2001) 17-21
29. Walker U.A., and Brinkman K. An argument for mitochondrial toxicity in highly active antiretroviral therapy-induced lipoatrophy. AIDS 15 (2001) 1450-1452
30. Walker U.A., and Brinkman K. NRTI induced mitochondrial toxicity as a mechanism for HAART related lipodystrophy: fact or fiction?. HIV Med. 2 (2001) 163-165
31. Walker U.A., Setzer B., and Venhoff N. Increased long-term mitochondrial toxicity in combinations of nucleoside analogue reverse-transcriptase inhibitors. AIDS 16 (2002) 2165-2173